Most anaesthetists would accept that halothane is a rare cause of postoperative hepatitis. However, whether enflurane is also a causative agent is more controversial. Since the introduction of enflurane in 1973 there have been few reports of hepatitis following its use, despite the heightened awareness following recognition of halothane hepatitis. By 1987, an Australian case report 1 brought to six the total number of deaths from hepatitis of unknown aetiology following enflurane anaesthesia, yet none is wholly convincing, mostly because of an inability to exclude infectious causes.
CASE REPORT
A 36-year-old 80kg female was admitted to our Day Procedure Unit for an examination under anaesthesia and repair of anal fissure. Her surgical history included a cholecystectomy nine years previously under enflurane-nitrous oxide anaesthesia (1.5 hours duration), after which her postoperative recovery had been uneventful. One year previously she had a dilatation and curettage (D&C) performed under isoflurane anaesthesia and seven months prior to the current admission she had a further D&C performed, again using isoflurane. She had no history of hepatic disease, recent travel, sexual contact or intravenous drug use. She had never had a blood transfusion. She had suffered from mild atopy (allergic rhinitis and eczema) but was not asthmatic. She was a nonsmoker, non-drinker and was taking no medication. Preoperative assessment was essentially normal. Her blood pressure was 100/55 mmHg.
After pre-oxygenation, the patient was given morphine 10 mg, metoclopramide 20 mg and induced with propofol 200 mg. A laryngeal mask airway was inserted and anaesthesia was maintained with nitrous oxide, oxygen and enflurane at an inspired concentration of 2%. The duration of anaesthesia was 15 minutes. Pulse oximetry remained at 100%, end-tidal carbon dioxide 40 mmHg, systolic blood pressure ranged between 80 and 90 mmHg and the heart rate between 70 and 80 beats per minute.
Postoperatively she was initially well but complained of nausea and then vomited about two hours after the anaesthetic. The nausea persisted and four hours later she complained of right subcostal pain. She was assessed by the resident medical officer and admission arranged. .ull blood examination was within normal limits. There was no eosinophilia. Urea and electrolytes were also within normal limits, but the liver function tests (L.Ts) were markedly abnormal ( Table 1 ). She remained in hospital for three days, by which time her L.Ts were normalizing and she was constitutionally much improved. At no time was she obviously jaundiced, nor did she develop a rash. Serological tests were ordered under the guidance of the Director of the Microbiology Department ( Table 2 ). At review one week later, the L.Ts were normal but the patient, though improving, still felt washed out, partly due to ongoing pain from her operation.
DISCUSSION
This report describes a previously well woman who developed acute postoperative hepatitis, for which there was no evidence preoperatively. Whilst it is very tempting to diagnose enflurane-induced hepatitis, this is an extremely rare condition and one should be wary when the diagnosis is one of exclusion. Even if it exists as a clinical entity it has a markedly lower incidence than that of false-negative serological tests. The other drugs given to the patient have a low incidence of adverse effects on the liver. Morphine can cause intense spasm of the sphincter of Oddi but the biochemical results produce an obstructive picture (with elevated serum alkaline phosphatase). No evidence of hepatoxicity has been demonstrated with propofol 2 . Splanchnic haemodynamics and liver oxygenation are well-maintained during propofol anaesthesia in rat 3 and dog 4 models, with no evidence of changes in liver function tests after propofol anaesthesia in humans [5] [6] [7] .
In 1983 Lewis et al 8 reviewed the details of the ten published cases and a further 48 unpublished cases of hepatitis associated with enflurane reported to the US .ood and Drug Administration (.DA) and the Armed .orces Institute of Pathology (A.IP). They concluded that the clinical, biochemical and histologic similarities between the reported cases and the accepted presentation of halothane hepatitis justified the view that enflurane-associated hepatic injury was a clinical entity. In a cogent editorial Dykes 9 disagreed with their conclusions. In 1986 Eger et al 10 reexamined the material and added further published and unpublished reports to the .DA and A.IP, a total of 88 cases. They divided the cases (after exclusion of reports with inadequate data) into two groups (unlikely and possible enfluraneassociated hepatitis) and then compared them. There were few differences and they concluded that there was little evidence to implicate enflurane as a causative agent for postoperative hepatitis. The case against enflurane could be strengthened by postulating a mechanism by which enflurane might cause hepatic injury. There have been several mechanisms proposed by which halothane might cause liver damage 11 . Hypovolaemia and hypoxia increase the severity of hepatic lesions in rats exposed to halothane, as does liver enzyme induction using in vitro experiments. This supports a theory of reductive metabolites of halothane provoking hepatic injury, yet none has yet been shown to be directly hepatotoxic. More promisingly, specific IgG antibodies have been detected in some patients with hepatic failure following exposure to halothane 12 . These antibodies are directed against an oxidative metabolite combined with hepatocyte surface proteins trifluoroacetyl (T.A) proteins. The formation of neo-antigens and an immunological response offers the most promising explanation of hepatic failure after repeated exposure to halothane but the validity of the immunological tests is yet to be proven. A more detailed analysis of the evidence is included in a comprehensive review by Elliot and Strunin 11 . Lewis et al 8 speculated that there might be some cross-sensitivity between halothane and enflurane and a case report from 1985 13 supports this. .urther work by Christ et al 14 showed that oxidative products of enflurane metabolism can produce T.A proteins that can be recognized by antibodies from patients with halothane hepatitis. Since the metabolism of enflurane is much less than that of halothane (2 to 8% versus 20 to 46%), then the incidence of postoperative liver dysfunction would be expected to be much less, and even rarer with isoflurane and desflurane 11 . Sevoflurane is metabolized by a different route and there have been no reports of hepatic failure associated with its use.
Despite the reservations outlined above, this case of acute onset, transient hepatitis seems more convincing than most (no previously reported cases have been able to exclude Hepatitis C). There was little that could have been done to further clarify the diagnosis, except a liver biopsy (clinically not indicated). There were no other obvious causes that might lead to the clinical picture described. It is impossible to exclude completely an infectious cause, although it seems unlikely in view of the acute onset postoperatively, the subsequent course of the illness and the laboratory results.
What would be the most appropriate anaesthetic management for this or any other patient with a history suspicious of hepatitis associated with the use of a volatile anaesthetic agent? Whilst there remains a question mark over the potential of cross-sensitivity it may be circumspect to avoid all volatile agents. Possible alternatives include total intravenous anaesthesia and regional blockade.
